Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights that acne is a common issue for transgender men undergoing testosterone therapy, with management generally following similar guidelines as for cisgender individuals.

In this case report, a 25-year-old transgender woman on testosterone-blocking therapy developed generalised hypertrichosis after starting ciclosporin for severe plaque psoriasis, illustrating that ciclosporin can induce this side effect even under androgen suppression.

This study of monozygotic transgender male twins observed that consistent hormone therapy led to physical changes such as deepening voice and increased facial/body hair, with no reported mood-related adverse effects.

This study systematically reviewed dermatological conditions affecting transgender and gender-diverse individuals, highlighting that testosterone therapy can induce acne in 25–88% of transgender men and alopecia after over two years, while dermatologic care must consider both medical and social complexities.

This study found that among transgender and gender diverse adults, facial hair is important for gender affirmation but often causes dissatisfaction and financial strain due to inadequate insurance coverage for hair care treatments.

In this narrative review, the authors discuss the potential impact of hormone therapy on androgenetic alopecia among transgender individuals, especially transgender men using testosterone, and its adverse effects on emotional well-being and body image within a socially stigmatized population.

In this case review, researchers describe a 17-year-old transgender male experiencing clitoromegaly, hirsutism, and oligomenorrhea, investigating conditions like PCOS and non-prescription testosterone use for gender affirmation, and highlighting the importance of gender-affirming care to improve mental health outcomes.

This review reports that transgender individuals undergoing hormonal therapy for gender transition face increased risks of cardiovascular disorders, brain tumors, changes in bone density, metabolic disorders, and other health issues, while highlighting the necessity of this therapy for gender transformation.

This study found that dermatologic concerns such as acne, androgenic alopecia, and eczema are prevalent among transgender and gender-diverse youth at Boston Children's Hospital, with acne notably linked to testosterone use, but noted low dermatology referral rates.

This case report describes a 10-year multidisciplinary treatment of a transgender woman in Slovenia, reporting a successful medical and social transition with stable emotional health, abstinence from alcohol, and no regrets following her transition.

This review outlines common dermatological disorders in transgender patients related to hormone therapy and surgeries but presents no new clinical findings; the authors emphasize the need for inclusive healthcare training.

This article discusses the effectiveness of gender transition procedures in alleviating gender dysphoria and the need for better models to understand their mechanisms, but reports no new clinical results.

This case report describes a transgender woman who achieved a soft, feminine hairline nine months post-hair transplant using follicles from both the occipital scalp and pubic area.

This article examines the care and health challenges faced by transgender or gender incongruence individuals, reporting no new clinical results; it highlights the importance of an individualized approach for optimizing well-being.

This review discusses dermatologic issues specific to transgender patients undergoing hormonal therapy and offers guidance for dermatology providers, but does not report new clinical results.

This study found that transgender patients on masculinizing hormone therapy had a higher likelihood of developing acne compared to cisgender women, and were more likely to experience AGA compared to cisgender women.

This study found that expression of certain mutant keratin genes in mice led to severe alopecia, suggesting a similar mechanism could cause hair loss in humans.

This review highlights the need for tailored hormonal treatment strategies for non-binary transgender individuals, emphasizing personalized care to enhance psychological well-being and quality of life.

In this study, stress experienced by transmen during early stages of gender transition was associated with reduced nocturnal blood pressure decline and increased C-reactive protein levels.

In this retrospective study, cyproterone acetate treatment in late-pubertal trans-girls was found to be generally safe and led to mild feminizing effects, with more rapid feminization occurring when combined with estrogens.

This article states that hormone therapy with estrogens and antiandrogens for transgender females is within an obstetrician-gynecologist's practice scope and involves careful dosing and monitoring to manage short-term thrombotic risks.

This article provides a framework for understanding hair disorders and treatment options in transgender individuals undergoing hormonal therapy and reports no new clinical results.

This study suggests that gender-affirming testosterone therapy in transgender men is generally safe and effective with adequate screening and monitoring, although high-quality long-term studies are lacking.

This review describes current medical and surgical treatments for transgender men, highlighting the effectiveness and general tolerability of hormone treatment, and suggesting that surgical benefits often surpass associated risks, although it reports no new clinical findings.

This review discusses hormonal and surgical gender-affirming interventions for transfeminine individuals, noting improvements in quality of life and mental health with minimal adverse effects, but reports no new research findings.

This review discusses the challenges and research gaps in transgender health care, highlighting the need for dedicated research infrastructure and funding to develop a more comprehensive evidence base.

This review outlines best practices for providing culturally competent care to transgender patients and discusses considerations for assessing disease risk, but reports no new research findings.

This review highlights the association between gender-affirming hormone therapy and increased cardiovascular risk among transgender individuals, emphasizing the need for cardiovascular-focused clinical management and further research to inform and educate both clinicians and patients.